IM Cannabis Prices $1.31M Registered Direct Offering at $2.00 — 66% Dilution to Existing Holders
IMCC sits 91% above its 52-week low of $1.55 on elevated volume (11× avg).
Summary
IM Cannabis priced a 655,000-share registered direct offering at US$2.00 per share, raising about US$1.3 million. The deal increases the share count by 66% and follows a string of dilutive convertible note financings. Invest-Pro, where director Eli Zamir serves as a director, bought 164,585 shares for $329,170, about 25% of the offering, and the company used financial hardship exemptions to avoid minority shareholder approval for the related party transaction.
Updated with a PR Newswire report · What changed
Updates
· SEC 6-K — The 6-K attaches the press release and confirms the offering closed on September 24, 2026, with Invest-Pro buying 164,585 shares for $329,170.
· PR Newswire — Invest-Pro, where director Eli Zamir serves as a director, bought 164,585 shares for $329,170, about 25% of the offering. The company used financial hardship exemptions to avoid minority shareholder approval for the related party transaction.
Key Events · Financing and Capital Events · IMCC
-
Updated · · PR Newswire
Registered Direct Offering Priced with Related Party Participation
655,000 common shares sold at US$2.00 per share for gross proceeds of approximately US$1.31 million, with no placement agent or underwriter fees. Invest-Pro, where director Eli Zamir serves as a director, bought 164,585 shares for $329,170, about 25% of the offering, and the company used financial hardship exemptions to avoid minority shareholder approval for the related party transaction.
-
66% Share Count Increase
Common shares outstanding rise from 992,494 to 1,647,494 after the offering — a 66% increase that significantly dilutes existing holders.
-
Deep Discount to Market
Offering price of US$2.00 is less than half the US$4.14 closing price on September 22, 2026, reflecting the company's distressed financing position.
-
Dilution to New Investors
Net tangible book value per share improves from negative US$10.55 to negative US$3.20 after the offering, but new investors face immediate dilution of US$5.19 per share.
Analysis · IMCC · Life Sciences
IM Cannabis is selling 655,000 shares at US$2.00 each, raising roughly US$1.3 million. The offering price is less than half the US$4.14 closing price on September 22, 2026, and the share count jumps from 992,494 to 1,647,494 — a 66% increase. The company has been running a series of deeply dilutive convertible note financings and reported going concern doubts in August, so this steeply discounted equity raise is a continuation of survival financing. The dilution table shows new investors immediately lose US$5.19 per share in net tangible book value, while existing holders see their book value improve by US$6.19 per share — a transfer of value from new buyers to the company. Invest-Pro, where director Eli Zamir serves as a director, bought 164,585 shares for $329,170, about 25% of the offering, and the company used financial hardship exemptions to avoid minority shareholder approval for the related party transaction. The company regained Nasdaq compliance on September 23, 2026, but the financing pattern suggests ongoing cash pressure.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.6% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.62%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.55 to $77.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.